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Abstract
Objective: Microbial translocation (MT) is thought to be a major contributor to the pathogenesis of HIV-related immune
activation, and circulating lipopolysaccharide (LPS) from Gram-negative bacteria is the principle measurement of this
process. However, related research has been impeded by inconsistent LPS test results.
Methods: Specimens were obtained from HIV-infected adults enrolled in the PEARLS study (ACTG A5175) and HIV-HCV co-
infected participants enrolled in a study of liver disease staging using MRI elastography. Pig-tailed macaque specimens were
obtained from SIV-infected and –uninfected animals. Samples were tested for LPS using the LAL assay with diazo-coupling
modifications to improve sensitive detection.
Results: When exogenous LPS was added to macaque plasma, .25% inhibition of LPS detection was found in 10/10 (100%)
samples at 20% plasma concentration compared to control; in contrast 5/10 (50%) samples at 2% plasma concentration
(p=0.07) and 0/10 (0%) at 0.1% plasma concentration (p=0.004) showed .25% inhibition of LPS detection. Similarly, when
LPS was added to human serum, .25% inhibition of LPS detection was found in 5/12 (42%) of samples at 2% serum
concentration compared to control, while 0/12 (0%) of samples in 0.1% serum showed .25% inhibition of LPS detection
(p=0.07). Likewise, LPS detection in human sera without exogenous LPS was improved by dilution: LPS was detected in 2/
12 (17%) human samples in 2% serum, ranging from 3,436–4,736 pg/mL, compared to 9/12 (75%) samples in 0.1% serum,
ranging from 123 pg/mL –60,131 pg/mL (p=0.016). In a separate validation cohort of HIV-HCV co-infected participants
sampled at two different times on the same day, LPS measured in 0.2% plasma and with diazo-coupling was closely
correlated between the first and second samples (R=0.66, p,0.05).
Conclusions: Undiluted serum and plasma mask LPS detection. The extent of MT may be substantially underestimated.
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Introduction
Human immunodeficiency virus (HIV) progression to AIDS is
associated with immune activation. [1] One proposed pathway for
immune activation in HIV/AIDS is HIV-induced intestinal CD4+
T-cell depletion that alters intestinal immunity and enhances
microbial translocation (MT) of commensal bacteria products (i.e.
the ‘‘leaky gut’’ hypothesis). The cardinal expression of MT is
blood lipopolysaccharide (LPS), the cell wall component of Gram-
negative enteric organisms. Brenchley et al. found that persons with
HIV infection and CD4+ T-lymphocyte depletion had higher
levels of plasma LPS than controls using the Limulus Amebocyte
Lysate (LAL) assay. [2] This finding was confirmed by some, but
not all, studies of HIV and simian immunodeficiency virus (SIV)
infection.[2–8] Inconsistencies in this literature do not appear to
be explained by differences in the research subjects or study
design, raising the hypothesis that limitations in the LPS assay itself
might contribute.
Conventional LPS detection exploits an enzymatic clotting
reaction in the horseshoe crab, Limulus polyphemus. The LAL assay
couples the reaction with catalysis of a colorimetric substrate. The
LAL assay is sensitive at detecting 1–10 pg/mL LPS, although this
PLoS ONE | www.plosone.org 1 August 2012 | Volume 7 | Issue 8 | e41258sensitivity is compromised by mammalian serum. [9,10] In this
study, we demonstrate LPS masking by serum and plasma from
HIV- and SIV-infected hosts and uninfected controls using the
LAL assay. We identified that LPS detection is only interpretable
at concentrations far below the range typically used, a finding that
has important implications for all LPS-related research including
studies of the pathogenesis of HIV and SIV infection.
Methods
Plasma and serum were derived from three sources. The first
source was plasma from 10 pigtailed macaques that were collected
pre- and post-SIV infection (42 days post-infection) as part of
ongoing studies of SIV progression and the use of antiretroviral
therapy (ART). The second source was human serum obtained
from the ACTG study A5175, a completed HIV treatment trial
assessing responses to ART in diverse international settings. To
validate that LPS masking is a generalized phenomenon in HIV
infection, a third source of plasma was obtained from HIV-
Hepatitis C virus (HIV-HCV) co-infected subjects who were
recruited for a study of magnetic resonance elastography to
determine liver disease stage. In this study plasma was obtained
and tested for LPS at two different times during the same day in 10
subjects, before and after magnetic resonance elastography. All
macaque and human specimens were stored at 280uC on-site or
in the testing laboratory. Aliquots were thawed on the day of
testing and tested in batch.
LPS was measured using the LAL assay (LONZA, Walkersville,
MD) as previously published but with the following modifications,
unless otherwise stated. [3] A) Samples were diluted in LPS-free
10 mM MgCl2 (LONZA, Walkersville, MD) in series from 1:5
(20% concentration) to 1:1000 (0.1% concentration) and divided
into two aliquots; a known amount of LPS (25 or 50 pg/mL) was
added to the first tube (referred to as ‘‘exogenous LPS’’), whereas
none was added to the second (referred to as ‘‘naı ¨ve’’). B) Samples
were heated to 80uC for 12–15 minutes, transferred to LPS-free
flat-bottomed 96-well plate (LONZA, Walkersville, MD) and kept
at 37uC for testing. Background values were obtained at 405 and
540 nm. C) The assay was performed according to the
manufacturer’s protocol but stopped by the addition of diazo-
Figure 1. Correlation between background and final absorbance results (raw or corrected by background subtraction) in dilutions
of SIV-infected and -uninfected macaque plasma samples tested for LPS content. Shown are bivariate analyses of background absorbance
values and final absorbance (A and C) or corrected final absorbance (final absorbance minus background; B and D) read at their respective
wavelengths: (A and B) final absorbance values were measured at 405 nm in the absence of the diazo-coupling modification or (C and D) at 540 nm
after performing the diazo-coupling modification. Dilutions are color-coded (20% plasma concentration in red, 2% in blue, 1% in green, 0.5% in
purple, 0.2% in gray). *Correlation and significance values marked with asterisks were calculated after removing all points representing 20% plasma
(in red). Spearman’s correlation was used for all analyses.
doi:10.1371/journal.pone.0041258.g001
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imetric change that is best detected at 540 nm (OD540). [11]
Samples were then measured at 540 nm and LPS quantities were
derived from a standard curve of known LPS concentrations.
Spearman estimation was used to correlate the background and
final absorbance. The proportion of inhibited samples at different
concentrations was compared using McNemar’s exact test for non-
parametric data, and paired t-tests were used to compare mean
inhibition in the same samples at different concentrations.
Ethics Statement
Study approval was obtained from the Institutional Review
Boards (IRB) at sites of sample collection and testing (Table S1).
Informed consent was obtained for the collection and storage of
serum and plasma specimens from ACTG study A5175 partici-
pants and from magnetic resonance elastography study partici-
pants. In ACTG A5175, the Johns Hopkins University In-
stitutional Review Board allowed a waiver for additional
consent, since samples were de-identified, the research involved
no more than minimal risk to subjects, and the waiver would not
have adversely affect the rights and welfare of the subjects.
Subjects in the magnetic resonance elastography study were
specifically consented to measure LPS in their collected plasma.
The study of SIV pathogenesis in pigtailed and rhesus monkeys
was approved by the Johns Hopkins University Institutional
Animal Care and Use Committee (IACUC). In the parent study,
all efforts were made to limit the amount of pain and discomfort
that these animals may have experienced during the course of
infection. Appropriate medical and support care was provided as
necessary. When invasive procedures were performed, intra- and
post- procedural analgesics were administered along with anti-
biotics if needed.
Results
LPS Detection in Macaque Plasma Samples
All macaques were male with median age (IQR) of 4 (3–4.5)
years. The median (IQR) CD4+ T-lymphocyte counts at the time
of testing were 1394 (1086–1584) cells/mL for uninfected
macaques and 373 (343–496) cells/mL after SIV infection. Median
(IQR) SIV RNA for infected macaques at time of testing was 6.7
(5.8–7.3) log10 copies/ml. Initial LPS testing of SIV-uninfected
and -infected plasma was performed in 20% plasma, as was
described previously. [2] Visual inspection of the samples at this
concentration revealed heightened turbidity. In the absence of
diazo-coupling, the median background values were closely
correlated to the absorbance values at the completion of the assay
(r=0.97, p,0.0001, Fig. 1A), and appeared to explain much of
the corrected final absorbance values (r=0.74, p,0.0001,
Fig. 1B). Serially diluting each sample diminished some but not
all background readings. After performing the diazo-coupling
modification, the dependence of final on background absorbance
values reduced in all plasma concentrations except the highest
(20%), where it persisted (Fig. 1C-D): the correlation between
background and corrected final absorbance values decreased when
the measures in 20% plasma concentration were excluded from
the analysis (r=0.35, p=0.0013 for all samples vs. r=0.07,
p=0.71 for all samples excluding those measured in 20% plasma).
The signal-to-noise ratio at this concentration masked detection of
LPS in SIV-infected and -uninfected samples in spite of the diazo-
coupling modification, prompting further study.
Exogenous LPS (50 pg/mL) was added to different concentra-
tions of plasma (0.1% to 20%) from uninfected macaque and SIV-
infected macaques, and compared to a control sample with the
same amount of LPS added to diluent alone. Strikingly, 10/10
(100%) samples in 20% plasma had .25% lower OD540 values
(.25% inhibition) compared to control (Fig. 2A). In contrast, 5/
10 (50%) of samples in 10% plasma had .25% inhibition
(p=0.07), and 0/10 samples in 0.2% plasma showed .25%
inhibition (p=0.004). Importantly, relative differences in in-
hibition that were found between samples in 20% plasma were
not preserved in 0.2% plasma. To validate that LPS masking in
SIV infection can be generalized, plasma samples from 10 SIV-
infected macaques were tested in a separate laboratory and with
a second operator. Compared to a control sample with a known
amount of LPS, 9 of 10 samples in 20% plasma had .25%
inhibition; in contrast, 0 of 10 samples in 0.2% plasma had .25%
inhibition (p=0.008; Fig. 2B). Naı ¨ve samples (without exogenous
LPS) were tested in triplicate for LPS and results were found to be
consistently more sensitive at paradoxically lower concentrations:
samples tested in 0.2% plasma had mean (SD) LPS concentrations
of 633 (118) pg/mL, compared to the same samples tested in 20%
plasma that had mean (SD) LPS concentrations of 18 (15) pg/mL
(p,0.001, data not shown).
Figure 2. LPS masking in macaque plasma. Exogenous LPS was added to samples at a fixed concentration of LPS (50 pg/mL) from a reference E.
coli standard after dilution in 10 mM MgCl2, as indicated. LAL testing with diazo-coupling was performed on all samples and each result was
compared to an LPS standard at the same concentration in diluent alone. A) Plasma samples from 10 uninfected and SIV-infectemacaques were
diluted from 20% (1:5 dilution) to 0.2% (1:500 dilution). Levels of no inhibition (black line) and 25% inhibition (red line) are indicated. B) Plasma
samples from 10 SIV-infected macaques were diluted and measured in 20% and 0.2% concentration. Shown are mean 6 SD for each animal. *Mean
percent inhibition was compared between the indicated concentrations using the paired t-test.
doi:10.1371/journal.pone.0041258.g002
Table 1. Characteristics of twelve randomly selected HIV-
infected adult participants from the ACTG A5175 cohort and
ten HIV-HCV co-infected adult participants from the Magnetic
Resonance Elastography (MRE) study.
ACTG 5175 MRE
N=12 N=10
Median Age, years (IQR) 31.5 (27.5–35.3) 47.5 (44.5–52.3)
Male, n (%) 4 (33.3) 5 (50)
Black, n (%) 8 (66.7) 9 (90)
On Antiretrovirals,
n( % )
7 (58.3) 10 (100)
Median CD4+
T lymphocytes/mm
3
(IQR)
244 (212–384) 269 (220–334)
Median HIV-1
RNA log10 copies/mL
(IQR)
2.6 (2.3–4.0) Median ,50
Median Baseline ALT
(U/L) (IQR)
25 (20–30) 42 (36–69)
HCV RNA log10 IU/mL NA 6.58 (5.84–6.76)
All MRE patients were HCV genotype 1; 2 (20%) had biopsy-proven cirrhosis.
doi:10.1371/journal.pone.0041258.t001
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Human serum samples from 12 HIV-infected adults were tested
in parallel, and their characteristics are shown in Table 1. LPS
was measured in samples tested in concentrations ranging from
2% and 0.1% serum (Fig. 3A). Mean (SD) LPS inhibition in 2%
serum was 38% (35%), and ranged from 24% to 98%. Subjects
with inhibition of LPS detection were indistinguishable from those
without inhibition on the basis of their CD4+ T-cell count, HIV
RNA level, or use of ART (data not shown). The mean (SD)
inhibition of LPS detection improved to 3% (9%) in 0.1% serum
and ranged from 211% to 13%. The proportion of samples with
.25% inhibition decreased from 5 of 12 (42%) in 2% serum to 0 of
12 (0%) in 0.1% serum (p=0.07); only 3 of 12 (25%) samples in
0.1% serum had .10% inhibition compared to 10 of 12 (83%) in
2% serum (p=0.008). When naı ¨ve samples from the same HIV-
infected individuals were diluted, a heightened sensitivity to detect
LPS was observed; LPS was detected in 2 of 12 samples (17%) at
2% plasma, ranging from 3,436–4,736 pg/mL, and in 9 of 12
(75%) samples in 0.1% plasma, ranging from 123 pg/mL –
60,131 pg/mL (p=0.016).
LPS Detection in Human Plasma Samples
To confirm that LPS masking is a general phenomenon in
persons with HIV, and not limited to human serum, inhibition was
validated in a separate group of 10 persons with HIV-HCV co-
infection who were enrolled in a study of magnetic resonance
elastography to measure the severity of liver disease. In this study,
subjects had phlebotomy performed several times during the day,
before and after elastography, from which plasma was collected.
LPS was measured in 2 time-separated samples from each person,
and testing was performed in 20% plasma and 0.2% plasma, with
and without the addition of exogenous LPS. In samples in which
exogenous LPS was added, the mean (SD) LPS inhibition in 20%
plasma was 51% (16%) and ranged from 30% to 79%. In contrast,
the mean (SD) LPS inhibition in 0.2% plasma was 12% (10%),
and ranged from 2% to 28% in samples with exogenously added
LPS (p,0.001; Fig. 3B). While LPS was not detectable in any
naı ¨ve plasma sample tested in 20% plasma, LPS was detectable in
all naı ¨ve plasma samples tested in 0.2% serum, and ranged from
471–1,586 pg/mL. In addition, replicate testing demonstrated
that LPS detection was precise, both within a sample and between
time points, for the same subjects (Fig. 4A). Notably, LPS
measured from naı ¨ve samples in 0.2% plasma was closely
correlated in the same subjects tested at two different times on
the same day (R=0.66, p,0.05; Fig. 4B).
Conclusion
In this study we demonstrate that serum and plasma in HIV and
SIV infection mask the detection of LPS using the LAL assay.
Additionally, we report a method that enhances LPS detection.
These results may have significant implications for studies of the
pathogenesis of HIV infection and others for which LPS
quantification is essential.
LPS is a heterogeneous collection of molecules that is found in
the cell wall of most Gram-negative bacteria. [12] The
fundamental structure of LPS, however, is conserved; it is
composed of an inflammatory Lipid A domain, a core oligosac-
charide, and a polysaccharide O-antigen. [13] Circulating LPS
has been found in hosts with Gram-negative bacterial infections,
and can act as a pathogen-associated molecular pattern that
stimulates an innate immune response by binding to the Toll-like
receptor 4 (TLR4) complex. [13] TLR4 binding triggers
a downstream cascade that results in the up-regulation of pro-
inflammatory cytokines such as tumor necrosis factor-a, and can
be critical for priming an adaptive immune response. [12].
In HIV-infected patients there is mounting evidence that
continued disease progression despite ART is due to systemic
immune activation, a state wherein levels of inflammatory
cytokines and markers of cellular activation are elevated.
[1,2,14] Brenchley et al. linked intestinal CD4+ T-lymphocyte
depletion in HIV infection to immune activation by demonstrating
increased amounts of LPS circulating in individuals with chronic
HIV infection and AIDS compared to uninfected persons and
persons with early HIV-1 infection; the authors found similar
evidence of MT in SIV-infected Rhesus macaques. [2] In contrast,
Redd et al. did not find any association of LPS levels with AIDS
progression in a longitudinal African cohort of HIV-infected
persons, despite the presence in that cohort of persons with rapid
disease progression. [4] Understanding these discordant results will
require further testing, but already concerns have been raised that
the conventional detection of LPS may lead to inconsistent results.
[6] Our findings illustrate the difficulty in measuring LPS in HIV
and SIV infection unless LPS masking is considered.
Inhibition of LPS detection has been described previously.
[9,10] While attempts have been made to identify the assay-
inhibiting agent, none have been revealing. It is clear, however,
that LPS recovery from serum and plasma can be improved at
paradoxically low sample concentrations. Past reports have
demonstrated that 1–10% serum concentrations have been
sufficient to mitigate LAL inhibition, but those studies were not
performed in HIV or SIV-infected samples. [9,10] In the present
study inhibition was diversely found in macaques and in humans,
and concentrations as low as 0.2% were required for reliable
quantification of LPS in serum and plasma. In contrast, recent
studies of LPS detection in HIV or SIV-infected samples have used
serum and plasma concentrations of up to 20% (1:5 dilution) and
did not assess for inhibition.[2–4] Although dilution of samples to
0.1% concentration reduces the lower limit of detection, this is
balanced by the increased sensitivity of detection. In this study,
serum and plasma dilution improved both the number of samples
with detectable LPS and the total amount of LPS found in each
sample.
Relative differences between LPS measurements might still be
valid if inhibition occurred to the same degree between samples at
a dilution, but are less interpretable if the amount of inhibition was
specimen-dependent. In this study we found that the range of LPS
inhibition in human serum varied from 24% to 98% at higher
concentrations, but decreased to 211% to 13% at concentrations
,0.5%, and similar results were found in plasma (Fig. 3). These
findings suggest that relative differences in LPS detection at higher
serum and plasma concentrations cannot be used as surrogates for
LPS amounts observed at lower concentrations.
Figure 3. LPS masking in HIV-infected persons. A) Exogenous LPS of a fixed concentration from a reference E. coli standard was added to
samples from 12 HIV-infected subjects that were diluted from 20% to 0.1% concentration. Levels of no inhibition (black line) and 25% inhibition (red
line) are indicated. B) LPS was measured in each of 20 samples from from 10 HIV-HCV co-infected subjects and compared to a known quantity of LPS
in assay diluent. The amount of inhibition was quantified for each specimen as a percent of the exogenously added LPS (100% indicates no assay
inhibition) and compared in aggregate between the same samples in 0.2% plasma and 20% plasma. *Mean percent inhibition was compared
between the indicated concentrations using the paired t-test.
doi:10.1371/journal.pone.0041258.g003
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PLoS ONE | www.plosone.org 7 August 2012 | Volume 7 | Issue 8 | e41258There are a variety of methods used to minimize LAL
inhibition, including heating samples before assay performance
as was done in our study. In addition, chloroform-based serum
extraction can reduce the amount of inhibition if sufficient starting
material is available. Diazo-coupling, specimen heating, and
sample dilution attenuated LPS masking inhibition in this study.
In this report we illustrate that serum and plasma from hosts
with HIV or SIV infection mask the detection of LPS more than
has been previously described in uninfected persons. Therefore it
is likely that earlier studies may have underestimated microbial
translocation. We recommend that future studies of microbial
translocation in HIV and SIV infection use a combination of
techniques to minimize LPS masking, including tested diluted
samples and employing diazo-coupling modifications.
Supporting Information
Table S1 International Testing Sites for ACTG study
A5175. Shown is the full list of each testing site and its associated
IRB that was responsible for approving the use of participants’
samples for study.
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